Mohit Bansal
Stock Analyst at Wells Fargo
(4.87)
# 40
Out of 4,479 analysts
109
Total ratings
70.42%
Success rate
21.5%
Average return
Main Sectors:
25 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $110 → $115 | $82.22 | +39.87% | 3 | Jun 27, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $540 → $555 | $473.78 | +17.14% | 8 | Jun 24, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $48 → $58 | $51.30 | +13.06% | 4 | Jun 7, 2024 | |
| NBIX Neurocrine Biosciences | Upgrades: Overweight | $140 → $170 | $137.49 | +23.65% | 7 | Apr 24, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Equal-Weight | $51 → $52 | $40.45 | +28.55% | 7 | Apr 18, 2024 | |
| MRK Merck & Co. | Maintains: Equal-Weight | $130 → $135 | $127.72 | +5.70% | 8 | Mar 27, 2024 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $84 → $78 | $68.40 | +14.04% | 7 | Mar 4, 2024 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Overweight | $20 → $14 | $6.22 | +125.08% | 2 | Mar 1, 2024 | |
| TVTX Travere Therapeutics | Maintains: Equal-Weight | $8 → $9 | $8.09 | +11.25% | 3 | Feb 16, 2024 | |
| BIIB Biogen | Downgrades: Equal-Weight | $315 → $240 | $228.82 | +4.89% | 8 | Feb 14, 2024 | |
| LLY Eli Lilly | Maintains: Overweight | $700 → $825 | $906.71 | -9.01% | 14 | Feb 7, 2024 | |
| PFE Pfizer | Maintains: Equal-Weight | $39 → $35 | $27.83 | +25.76% | 8 | Oct 17, 2023 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $875 → $980 | $1,044.66 | -6.19% | 9 | Aug 21, 2023 | |
| CERE Cerevel Therapeutics Holdings | Upgrades: Overweight | $30 | $41.23 | -27.24% | 3 | May 4, 2023 | |
| ABBV AbbVie | Maintains: Overweight | $200 → $195 | $165.96 | +17.50% | 3 | Apr 28, 2023 | |
| AMGN Amgen | Upgrades: Overweight | $275 → $265 | $310.77 | -14.73% | 5 | Mar 13, 2023 | |
| MLYS Mineralys Therapeutics | Initiates: Overweight | $27 | $12.09 | +123.33% | 1 | Mar 7, 2023 | |
| XENE Xenon Pharmaceuticals | Initiates: Overweight | $50 | $36.56 | +36.76% | 1 | Nov 28, 2022 | |
| FBRX Forte Biosciences | Initiates: Buy | n/a | $0.52 | - | 1 | Mar 26, 2021 | |
| RDUS Radius Health | Maintains: Buy | n/a | $14.67 | - | 1 | Jan 7, 2021 | |
| STTK Shattuck Labs | Initiates: Buy | n/a | $3.64 | - | 1 | Nov 3, 2020 | |
| ADAP Adaptimmune Therapeutics | Maintains: Buy | n/a | $1.05 | - | 1 | Apr 27, 2020 | |
| CALA Calithera Biosciences | Maintains: Buy | n/a | $0.01 | - | 1 | Mar 27, 2020 | |
| AVTR Avantor | Maintains: Buy | n/a | $20.58 | - | 1 | Mar 20, 2020 | |
| BOLD Boundless Bio | Maintains: Neutral | n/a | $4.30 | - | 2 | Dec 10, 2018 |
BioMarin Pharmaceutical
Jun 27, 2024
Maintains: Overweight
Price Target: $110 → $115
Current: $82.22
Upside: +39.87%
Vertex Pharmaceuticals
Jun 24, 2024
Maintains: Overweight
Price Target: $540 → $555
Current: $473.78
Upside: +17.14%
Halozyme Therapeutics
Jun 7, 2024
Maintains: Overweight
Price Target: $48 → $58
Current: $51.30
Upside: +13.06%
Neurocrine Biosciences
Apr 24, 2024
Upgrades: Overweight
Price Target: $140 → $170
Current: $137.49
Upside: +23.65%
Bristol-Myers Squibb Company
Apr 18, 2024
Maintains: Equal-Weight
Price Target: $51 → $52
Current: $40.45
Upside: +28.55%
Merck & Co.
Mar 27, 2024
Maintains: Equal-Weight
Price Target: $130 → $135
Current: $127.72
Upside: +5.70%
Gilead Sciences
Mar 4, 2024
Maintains: Equal-Weight
Price Target: $84 → $78
Current: $68.40
Upside: +14.04%
Ironwood Pharmaceuticals
Mar 1, 2024
Maintains: Overweight
Price Target: $20 → $14
Current: $6.22
Upside: +125.08%
Travere Therapeutics
Feb 16, 2024
Maintains: Equal-Weight
Price Target: $8 → $9
Current: $8.09
Upside: +11.25%
Biogen
Feb 14, 2024
Downgrades: Equal-Weight
Price Target: $315 → $240
Current: $228.82
Upside: +4.89%
Eli Lilly
Feb 7, 2024
Maintains: Overweight
Price Target: $700 → $825
Current: $906.71
Upside: -9.01%
Pfizer
Oct 17, 2023
Maintains: Equal-Weight
Price Target: $39 → $35
Current: $27.83
Upside: +25.76%
Regeneron Pharmaceuticals
Aug 21, 2023
Maintains: Overweight
Price Target: $875 → $980
Current: $1,044.66
Upside: -6.19%
Cerevel Therapeutics Holdings
May 4, 2023
Upgrades: Overweight
Price Target: $30
Current: $41.23
Upside: -27.24%
AbbVie
Apr 28, 2023
Maintains: Overweight
Price Target: $200 → $195
Current: $165.96
Upside: +17.50%
Amgen
Mar 13, 2023
Upgrades: Overweight
Price Target: $275 → $265
Current: $310.77
Upside: -14.73%
Mineralys Therapeutics
Mar 7, 2023
Initiates: Overweight
Price Target: $27
Current: $12.09
Upside: +123.33%
Xenon Pharmaceuticals
Nov 28, 2022
Initiates: Overweight
Price Target: $50
Current: $36.56
Upside: +36.76%
Forte Biosciences
Mar 26, 2021
Initiates: Buy
Price Target: n/a
Current: $0.52
Upside: -
Radius Health
Jan 7, 2021
Maintains: Buy
Price Target: n/a
Current: $14.67
Upside: -
Shattuck Labs
Nov 3, 2020
Initiates: Buy
Price Target: n/a
Current: $3.64
Upside: -
Adaptimmune Therapeutics
Apr 27, 2020
Maintains: Buy
Price Target: n/a
Current: $1.05
Upside: -
Calithera Biosciences
Mar 27, 2020
Maintains: Buy
Price Target: n/a
Current: $0.01
Upside: -
Avantor
Mar 20, 2020
Maintains: Buy
Price Target: n/a
Current: $20.58
Upside: -
Boundless Bio
Dec 10, 2018
Maintains: Neutral
Price Target: n/a
Current: $4.30
Upside: -